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Abstract
Objective: To evaluate fatty acid plasma levels, phospholipase 
A2 activity, and the developmental profiles of children with autism 
vs. control subjects.
Methods: Twenty four children with autism underwent labora-
tory analysis for fatty acid quantification using gas chromatogra-
phy and PLA2 activity determination by fluorometric assay.
Results: No correlation was observed between the developmen-
tal quotient and fatty acid plasma levels. Phospholipase A2 acti-
vity was significantly higher among autistic children compared 
with controls.
Conclusion: The study did not show a correlation between fatty 
acid and phospholipase A2 plasma levels and the developmental 
profile of children with autism.
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Resumo
Objetivo: Avaliar os níveis plasmáticos de ácidos graxos, a 
atividade da fosfolipase A2 e o perfil de desenvolvimento de 
crianças com autismo versus controles.
Métodos: Vinte e quatro crianças com autismo foram 
submetidas a exames laboratoriais para quantificação plasmática 
de ácidos graxos por cromatografia gasosa e para determinação 
da atividade de fosfolipase A2 por ensaio fluorimétrico.
Resultados: Nenhuma correlação foi observada entre o 
coeficiente de desenvolvimento e os níveis plasmáticos dos 
ácidos graxos quantificados. A atividade da fosfolipase A2 foi 
significativamente maior no grupo de crianças com autismo 
quando comparado ao grupo controle.
Conclusão: O estudo não demonstrou correlação entre os 
níveis plasmáticos de ácidos graxos e fosfolipase A2 e o perfil de 
desenvolvimento de crianças com autismo.
Descritores: Transtorno autístico, ácidos graxos, fosfolipase A2.
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Introduction
Reduced levels of polyunsaturated fatty acids have been 
associated with some childhood mental disorders such as 
attention deficit hyperactivity disorder (ADHD) in boys,1,2 
severe deficits in reading, spelling, and auditory memory,3 
as well as dyslexia and developmental coordination disorder 
(DCD).4 Autism spectrum disorders (ASD) also seem to be 
associated with altered lipid metabolism in their pathogenesis. 
These alterations provoke changes in the structure and 
function of cell membrane phospholipids, similarly to what 
is observed in other developmental disorders.5,6 A significant 
reduction in the levels of polyunsaturated fatty acids in the 
red blood cell membrane of patients with autism reinforces 
this assumption.5,7
Recently, El-Ansary et al.8 evaluated fatty acid profile 
in the plasma of 26 autistic children and 26 age-matched 
healthy children. The authors found increased levels of most 
saturated fatty acids, except for propionic acid, and reduced 
levels of most polyunsaturated fatty acids. Moreover, 
omega-3 supplementation in children with ASD appears to 
be safe and effective in improving behavior.9
Also, children with ASD have been shown to present 
significantly higher phospholipase A2 (PLA2) activity.
7 In 
fact, evidence suggests that the instability observed in fatty 
acid levels may be caused by an increase in PLA2 activity, 
perhaps in association with the high oxidative stress found 
in these patients.10
In this context, the objective of this study was to 
evaluate fatty acid plasma levels, PLA2 activity, and the 




The study included children with autism and 
children who had no diagnostic features of any mental 
or behavioral disorder, or clinical symptoms that could 
indicate the occurrence of any other disease. Controls 
were matched for age and sex and were selected from 
the general population of the municipality of Juiz de 
Fora, MG, Brazil. The study protocol was approved by 
the Research Ethics Committee of Universidade Federal 
de Juiz de Fora (UFJF) (protocol no. 140/2007).
We initially selected 60 children aged 2 to 18 years with 
a diagnosis or possible diagnosis of autism from two local 
schools that agreed to participate in the study. Of these, 22 
were excluded because they had other mental disorders, 
neurological or sensory impairment possibly related 
development failure, such as congenital rubella syndrome 
associated with severe mental retardation, cerebral palsy, 
deafness, or blindness. Of the 38 patients who comprised the 
sample, 33 (all < 13 years) underwent neuropsychological 
testing, and 24 children with autism were finally selected 
for inclusion in the final sample. These 24 children were 
subjected to laboratory analysis for fatty acid quantification 
and PLA2 activity assessment.
Control children were selected from the same schools. The 
group initially comprised 32 children aged 2 to 12 years with 
no symptoms of mental disorders, no demands for health care 
services, and not using any drug. After neuropsychological 
testing, 24 children were selected to comprise the final 
control group and were subjected to laboratory analysis.
Neuropsychological assessment was performed by 
specialists according to diagnostic criteria set forth in the 
Diagnostic and Statistical Manual of Mental Disorders, 4th 
edition, Text Revision (DSM-IV-TR).11 Evaluation started 
with a clinical interview, following application of inclusion 
and exclusion criteria. In a second clinical interview, patients 
underwent psychiatric mental status examination according 
to Brazilian guidelines.12 Additional interviews were 
conducted whenever necessary to complete these steps.
Neuropsychological assessment was performed using 
the Psychoeducational Profile – Revised (PEP-R), an 
instrument created to assess developmental age in children 
with autism.13,14 The PEP-R assesses development and a 
range of behaviors characterized as an inventory of skills 
and behaviors designed to identify patterns of uneven and 
idiosyncratic learning. The development scale includes 
the following dimensions: gross motor coordination, fine 
motor coordination, visual motor coordination, perception, 
imitation, cognitive performance, and verbal cognition. The 
scale was applied by a neuropsychologist in a single meeting 
that lasted about 1 hour. The range of behavior scale, used 
to identify atypical behaviors, was applied but not used for 
correlation analysis purposes in the present study (results 
varied widely, probably because of the use of medications, 
and therefore were not related to the developmental age of 
children). The total score obtained for each patient or control 
yielded a certain age of development (AD). The quotient 
of development (QD) was calculated for patients using the 
formula QD = AD/chronological age in months x 100.
Computed tomography (CT) scans of the skull were 
obtained to exclude the presence of any neurological 
disease with symptoms similar to those found in children 
with autism.
Blood collection
Blood samples (10 mL) were collected by venipuncture 
of the peripheral forearm vein of autistic and control 
children using a 21G scalp vein set (Becton Dickinson, 
Franklin Lakes, USA). Blood was collected into two tubes, 
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one containing anticoagulant (lithium heparin) and another 
without anticoagulant, centrifuged at 1,811 x g for 15 
minutes at room temperature, and then stored in a freezer 
at -70 ºC until laboratory analysis. All materials were coded 
to preserve patient anonymity, and all procedures followed 
the principles of good laboratory practice.
Fatty acid quantification
Fatty acid levels were determined according to the 
method originally described by Folch et al.15 and modified 
by El-Ansary et al.8 Briefly, 200 μL of sample was extracted 
in the presence of internal standards and esterified fatty 
acid using 3N hydrochloric acid methanolic solution in sealed 
bottles under nitrogen. Samples were incubated at 100 ºC 
for 45 minutes. Fatty acid methyl esters were extracted 
with n-hexane, and fatty acid composition of the extract 
was analyzed using a gas chromatograph (Hewlett-Packard 
HP 5890 Series II Plus, Analytical Direct, Wilmington, USA) 
equipped with a flame ionization detector and using a 
capillary column of 30 m x 0.25 mm x 0.25 μm (Supelco-
Omegawax, Sigma-Aldrich, St. Louis, USA). The flow rate 
of helium was 1.2 mL/minute, with a separation/flow ratio 
of 50:1. Furnace temperature was 205 ºC. Injector and 
detector temperatures were 260 and 262 ºC, respectively. 
Two internal standards, C15:0 and C23:0, were added 
during analysis. Fatty acids (arachidonic acid [ARA], 
eicosapentaenoic acid [EPA], and docosahexaenoic acid 
[DHA]) were identified by comparison of retention times with 
authentic standards. Quantification of each fatty acid was 
expressed as weight percentage of total fatty acids present 
in the sample. Analyses were performed in duplicate.
PLA2 activity
PLA2 activity was determined by fluorometric assay 
using pyrene-labelled phospholipid analog 1-octosanyl-
2-(pyren-1-yl)-hexanoyl-sn-glycerophosphomethanol 
(C28-O-PHPM) as substrate. A total of 40 μL of serum was 
incubated at 37 ºC for 90 minutes in a buffer (final volume: 
200 μL) containing 30 μm of C28-O-PHPM and 14 μm of 
Tris/hydrogen chloride, pH 7.4. Following incubation, the 
reaction was stopped and the released pyrenylhexanoic 
acid extracted and quantified as described by Ross et al.16 
Serum blank reactions were stopped at zero time.
Statistical analysis
Results were analyzed using descriptive statistics. 
Correlations between parameters were assessed using 
Pearson’s correlation coefficient. Statistical analysis was 
performed using the Statistical Package for the Social 
Sciences (SPSS) version 13.0 for Windows.
Results
Patients
Mean age in the group of autistic patients (n = 24) 
was 7.4±2.9 years, and in the control group (n = 24), 
7.2±1.8 years (age range in both groups: 2-12 years). A 
total of 18 children were male in each of the groups (boy 
to girl ratio = 3:1).
In the week preceding blood collection, none of 
children had started the use of any new medication. Of 
the 24 autistic children, 21 (87.5%) were making use 
of psychotropic drugs to treat autism symptoms, under 
either monotherapy (n = 7) or polytherapy (n = 14). 
The drugs most frequently prescribed were risperidone 
and carbamazepine, used in combination with each other 
or with other drugs. Control children were not on any 
medication. None of the children in any group were using 
supplements containing omega-3 and/or omega-6.
In the patient group, nine children (37.5%) had a history 
of seizures during development. In the control group, none 
of the children reported the occurrence of seizures.
Application of the PEP-R scale of development yielded 
a total score based on the sum of points in the “Passed” 
category (1 point for each item in that category). 
Children diagnosed with autism had a mean score of 
31.12±23.75, compared to 120.79±19.21 in the control 
group. Mean score in the control group was 3.8 times 
higher than the mean score in the patient group (p < 
0.001). Mean AD was 66.54±15.97 in the control group 
and 16.64±8.91 in the patient group.
Patients were divided into two groups according to 
QD values for the assessment of correlations between 
the developmental profile of children and the parameters 
assessed. In the subset of QD < 15 (n = 11), mean QD 
was 10.42±4.18, and in the subgroup with QD > 15 (n = 
12), mean QD was 29.26±13.18.
Fatty acid quantification
ARA plasma levels (weight percentage of total fatty 
acids) were significantly elevated in autistic children 
(16.82±1.04 mmol L-1) compared with children in the 
control group (12.26±1 mmol L-1) (p < 0.001). EPA 
plasma levels were significantly reduced in autistic 
children (0.76±0.20 mmol L-1) when compared to 
controls (1.24±0.27 mmol L-1) (p < 0.001). The same 
was observed for plasma levels of DHA in the group of 
autistic children (3.67±0.65 mmol L-1) compared with 
the control group (4.95±0.65 mmol L-1) (p < 0.001). 
Analysis of correlations between plasma levels of 
fatty acids ARA, EPA, and DHA in both groups showed 
increased rates of ARA:EPA and ARA:DHA in autistic 
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children (p < 0.05) and reduced rates of EPA:ARA 
and EPA:DHA in the autistic group (p < 0.005) when 
compared to control children.
Among autistic children, no correlation was observed 
between QD and plasma levels of ARA (p = 0.81, r = 
-0.05), EPA (p = 0.39, r = -0.18), and DHA (p = 0.70, r 
= -0.08). Also, analysis of possible correlations between 
the two subgroups of autistic children, namely those 
with QD < 15 (n = 11) and with QD > 15 (n = 13) and 
plasma levels of ARA (p = 0.90), EPA (p = 0.92) and 
DHA (p = 0.15) failed to find significant results.
PLA2 activity
PLA2 activity was significantly higher in autistic children 
(170±10 pMol min-1 mL-1, n = 24) when compared to the 
control group (132±8 pMol min-1 mL-1, n = 24) (p < 0.05).
Discussion
The demographic characteristics of our sample, with a 
larger share of male children, at a 3:1 ratio, corroborate the 
already known higher incidence of autism in boys, with ratios 
ranging from 3.5 to 4 boys for every girl.17 Even though 
this ratio may vary depending on the degree of intellectual 
function, among the six girls with autism in our study, one 
had a developmental age of 34, and all others, < 18. Among 
the girls in the control group, one showed a developmental 
age of 73, compared to 77 for all the others (data not 
shown). When autistic children were divided according to 
QD, four girls and seven boys were included in the subgroup 
with more severe developmental deficits (QD < 15). The 
subgroup with higher QD (> 15), in turn, included two girls 
and 11 boys. These data suggest a change in sex ratio, 
with a greater representation of women, especially when 
considering children with larger deficits in learning patterns, 
as indicated by Klin17 and by Mercadante & Rosário.18
According to Aman et al.,19 it is estimated that 46% of 
children with global development disorders are treated with 
psychotropic drugs to control symptoms. In our study, of 
the 24 children in the case group, 21 (87.5%) were using 
psychotropic drugs, and 14 children were using two or 
more psychotropic drugs to reduce symptoms associated 
with the autistic spectrum. Even though we have included 
solely children with autism and no other ASD, the frequency 
of prescriptions seems high and could be related to a poor 
implementation of health care routines, combined with a 
scarcity of specialized care in Brazil.20
With regard to fatty acid quantification results, high 
plasma levels of ARA and low levels of EPA and DHA 
were observed in the group of autistic children, which is 
consistent with the evidence of altered lipid metabolism 
in neuropsychiatric disorders. It has been proposed that 
such imbalance is related to changes in the structure and 
function of cell membrane phospholipids.5 In particular, 
the levels of EPA have been associated with the 
production of eicosanoids, which have anti-inflammatory, 
antithrombotic, and vasodilator properties8 and were 
reduced in the autistic children of our study.
The production of eicosanoids, a group of biologically 
active molecules derived mainly from ARA and released 
from the membrane by the PLA2 enzyme, seems to 
be particularly related to physiological dysfunctions 
characteristic of ASD. This group includes prostaglandins, 
leukotrienes, and thromboxanes, which act as second 
messengers, regulating a variety of physiological 
processes, and as mediators in inflammation. In addition, 
eicosanoids play important roles in the neurobiology of 
ion channels, receptors, release of neurotransmitters, 
synaptic plasticity, and neuronal gene expression. 
Prostaglandins E2 and D2 have sedative properties, and are 
involved in the control of the sleep-wake cycle.21 Elevated 
concentrations of ARA, such as those observed in our 
study, could be associated with pathological conditions.
DHA has a role in inhibiting neuronal apoptosis and 
regulating neuronal excitability,22 and it may also modulate 
abnormal electrical impulses in the neurons.23 A deficit 
of these fatty acids could be related to the increased 
susceptibility to seizures observed in patients with ASD 
and was observed in our group of autistic children.
Our results are consistent with those reported by Bell 
et al.24 Those authors also found an increase in ARA:EPA 
ratio in erythrocytes and plasma of autistic children 
vs. age-matched children with normal development. 
However, our findings are discordant with those of 
El-Ansary et al.,25 who observed reduced ARA:DHA 
and higher EPA:ARA ratios in autistic patients. These 
differences can probably be explained by fluctuations 
in EPA and DHA levels as a result of different dietary 
patterns, as the levels of ARA remain relatively stable.
Omega-3 supplementation has been associated with 
better results in behavioral assessment scales applied to 
autistic children.9 In addition, patients who receive EPA 
supplementation have been shown to present a reduced PLA2 
activity when compared with patients not supplemented.7 
These findings confirm that the children participating in our 
study were not using any dietary supplement.
The high levels of PLA2 activity observed in our autistic 
children are consistent with the report of Bell et al.7 
and provide further evidence of an association between 
accelerated phospholipid metabolism and biochemical 
alterations of the lipid membrane. In addition, El-Ansary 
et al.8 indicated a relationship between high levels of 
saturated fatty acids and high oxidative stress. Bell et 
al.7 also suggested that the increase in PLA2 activity 
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was associated with high oxidative stress, resulting in 
instability of the fatty acid profile. According to Tostes et 
al.,10 the increased levels of plasma nitric oxide observed 
in autistic children seem to corroborate this hypothesis.
Among the limitations of the study is the fact that 
we did not exclude children under treatment. The use of 
psychotropic drugs may have interfered with the results 
of laboratory tests and with the children’s behavior during 
assessment. However, Molloy et al.26 evaluated the levels 
of different cytokines (IFN-γ, IL-2, IL-4, IL-5, IL-10, and 
IL-13) in children with global development disorders 
and found statistically similar levels of these cytokines 
regardless of the use of psychotropic drugs (65% of the 
children were under treatment). Additionally, no significant 
inhibition of PLA2 activity was observed in the group of 
autistic patients, even though this secondary inhibition in 
response to neuroleptic drugs has been observed in both 
in vitro and in vivo animal experiments.27
In sum, autistic children show abnormalities in 
phospholipid metabolism and developmental profile. 
However, the present study did not show a correlation 
between fatty acid and phospholipase A2 plasma levels 
and the developmental profile of children with autism.
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